 NEWTON, Mass., April 19, 2021 PRNewswire -- Karyopharm Therapeutics Inc. Nasdaq:KPTI, a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that health-related quality of life HRQoL data from the Phase 3 portion of the SEAL Se linexor in A dvanced L iposarcoma study were published online in Future Oncology. 